Thus, validation of RAS wild-type status is mandatory to establish treatment in advanced CRC [30] and extended RAS testing investigating exons 2, 3 and 4 (codons 12, 13, 59, 61, 117 and 146) should be included, as only patients showing pan-RAS wild-type status should be treated with EGFR inhibitors according to current guidelines [5]. The gene discussed is EGFR; the disease is colorectal carcinoma.